Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Post-Transplantation Cyclophosphamide after Bone Marrow Transplantation Is Not Associated with an Increased Risk of Donor-Derived Malignancy.
Majzner RG, Mogri H, Varadhan R, Brown P, Cooke KR, Bolaños-Meade J, Swinnen L, Kanakry J, Luznik L, Jones RJ, Fuchs E, Ambinder R, Kasamon Y, Symons HJ. Majzner RG, et al. Biol Blood Marrow Transplant. 2017 Apr;23(4):612-617. doi: 10.1016/j.bbmt.2016.12.640. Epub 2017 Jan 3. Biol Blood Marrow Transplant. 2017. PMID: 28062216 Free PMC article.
Pulmonary function after hematopoietic stem cell transplantation is significantly better in pediatric recipients following reduced toxicity compared with myeloablative conditioning.
Majzner R, Sandoval C, Dozor AJ, Jin Z, van de Ven C, Dalal R, Morris E, Harrison L, Wolownik K, Fabricatore S, Baxter-Lowe LA, Cairo MS. Majzner R, et al. Bone Marrow Transplant. 2016 Nov;51(11):1530-1532. doi: 10.1038/bmt.2016.172. Epub 2016 Jun 20. Bone Marrow Transplant. 2016. PMID: 27322849 No abstract available.
T cell depletion utilizing CD34(+) stem cell selection and CD3(+) addback from unrelated adult donors in paediatric allogeneic stem cell transplantation recipients.
Geyer MB, Ricci AM, Jacobson JS, Majzner R, Duffy D, Van de Ven C, Ayello J, Bhatia M, Garvin JH Jr, George D, Satwani P, Harrison L, Morris E, Semidei-Pomales M, Schwartz J, Alobeid B, Baxter-Lowe LA, Cairo MS. Geyer MB, et al. Br J Haematol. 2012 Apr;157(2):205-19. doi: 10.1111/j.1365-2141.2012.09048.x. Epub 2012 Feb 8. Br J Haematol. 2012. PMID: 22313507 Free article. Clinical Trial.
Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins.
Blaeschke F, Stenger D, Apfelbeck A, Cadilha BL, Benmebarek MR, Mahdawi J, Ortner E, Lepenies M, Habjan N, Rataj F, Willier S, Kaeuferle T, Majzner RG, Busch DH, Kobold S, Feuchtinger T. Blaeschke F, et al. Among authors: majzner rg. Blood Cancer J. 2021 Jun 4;11(6):108. doi: 10.1038/s41408-021-00499-z. Blood Cancer J. 2021. PMID: 34088894 Free PMC article. No abstract available.
NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity.
Richards RM, Zhao F, Freitas KA, Parker KR, Xu P, Fan A, Sotillo E, Daugaard M, Oo HZ, Liu J, Hong WJ, Sorensen PH, Chang HY, Satpathy AT, Majzner RG, Majeti R, Mackall CL. Richards RM, et al. Among authors: majzner rg. Blood Cancer Discov. 2021 Sep 16;2(6):648-665. doi: 10.1158/2643-3230.BCD-20-0208. eCollection 2021 Nov. Blood Cancer Discov. 2021. PMID: 34778803 Free PMC article.
Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force.
Whittle SB, Offer K, Roberts RD, LeBlanc A, London C, Majzner RG, Huang AY, Houghton P, Alejandro Sweet Cordero E, Grohar PJ, Isakoff M, Bishop MW, Stewart E, Slotkin EK, Greengard E, Borinstein SC, Navid F, Gorlick R, Janeway KA, Reed DR, Hingorani P. Whittle SB, et al. Among authors: majzner rg. Pediatr Blood Cancer. 2021 Sep;68(9):e29188. doi: 10.1002/pbc.29188. Epub 2021 Jun 16. Pediatr Blood Cancer. 2021. PMID: 34137164 Free PMC article.
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.
Spiegel JY, Patel S, Muffly L, Hossain NM, Oak J, Baird JH, Frank MJ, Shiraz P, Sahaf B, Craig J, Iglesias M, Younes S, Natkunam Y, Ozawa MG, Yang E, Tamaresis J, Chinnasamy H, Ehlinger Z, Reynolds W, Lynn R, Rotiroti MC, Gkitsas N, Arai S, Johnston L, Lowsky R, Majzner RG, Meyer E, Negrin RS, Rezvani AR, Sidana S, Shizuru J, Weng WK, Mullins C, Jacob A, Kirsch I, Bazzano M, Zhou J, Mackay S, Bornheimer SJ, Schultz L, Ramakrishna S, Davis KL, Kong KA, Shah NN, Qin H, Fry T, Feldman S, Mackall CL, Miklos DB. Spiegel JY, et al. Among authors: majzner rg. Nat Med. 2021 Aug;27(8):1419-1431. doi: 10.1038/s41591-021-01436-0. Epub 2021 Jul 26. Nat Med. 2021. PMID: 34312556 Free PMC article. Clinical Trial.
Tumor Antigen Escape from CAR T-cell Therapy.
Majzner RG, Mackall CL. Majzner RG, et al. Cancer Discov. 2018 Oct;8(10):1219-1226. doi: 10.1158/2159-8290.CD-18-0442. Epub 2018 Aug 22. Cancer Discov. 2018. PMID: 30135176 Review.
CAR T Cell Therapy for Neuroblastoma.
Richards RM, Sotillo E, Majzner RG. Richards RM, et al. Among authors: majzner rg. Front Immunol. 2018 Oct 16;9:2380. doi: 10.3389/fimmu.2018.02380. eCollection 2018. Front Immunol. 2018. PMID: 30459759 Free PMC article. Review.
Tuning the Antigen Density Requirement for CAR T-cell Activity.
Majzner RG, Rietberg SP, Sotillo E, Dong R, Vachharajani VT, Labanieh L, Myklebust JH, Kadapakkam M, Weber EW, Tousley AM, Richards RM, Heitzeneder S, Nguyen SM, Wiebking V, Theruvath J, Lynn RC, Xu P, Dunn AR, Vale RD, Mackall CL. Majzner RG, et al. Cancer Discov. 2020 May;10(5):702-723. doi: 10.1158/2159-8290.CD-19-0945. Epub 2020 Mar 19. Cancer Discov. 2020. PMID: 32193224 Free PMC article.
47 results